New analyses examine Afrezza across pediatric A1c and efficacy, patient treatment satisfaction, use with AID algorithms and investigator-led ...
inbrija-1 Inbrija (levodopa inhalation powder; Acorda Therapeutics) is the first and only FDA-approved inhaled levodopa for intermittent treatment of OFF episodes in patients with Parkinson's disease ...
ProAir Digihaler ProAir® Digihaler® (albuterol sulfate; Teva) Inhalation Powder is now available for patients aged ≥4 years for the treatment or prevention of bronchospasm with reversible obstructive ...
Merz Therapeutics GmbH and Jiangxi Kvvit Pharmaceutical Co. Ltd. today announced that the companies have entered into an exclusive license and collaboration agreement regarding INBRIJA® (levodopa ...
MORRISVILLE, N.C., May 23, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, ...
AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its ...
March 2, 2006 — The US Food and Drug Administration (FDA) has approved orphan drug status for amphotericin B inhalation powder in the prevention of pulmonary fungal infections in patients at risk for ...
FDA's approval of YUTREPIA paves the way for prescribers to add a new treatment option for patients with PAH and PH-ILD YUTREPIA is designed to enhance deep-lung delivery with an easy-to-use device ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results